Transparency / aggregate spend: Raising compliance to the next level
Health reform in the US and on the global stage, Corporate Integrity Agreements (CIAs), Foreign Corrupt Practices Act (FCPA) investigations, individual accountability of senior executives, intense media and public scrutiny — all these drivers are converging to cause a "perfect storm" for pharmaceutical, medical device and life sciences companies who are already wrestling with the operational challenge of complying with a myriad of transparency regulations.
As a result of this "perfect storm", companies are working diligently to enhance traditional ways of addressing compliance while simultaneously working to leverage these investments to gain a competitive advantage through process optimization, reputational management, risk mitigation and better business intelligence.
Look for papers, articles, and case studies. See all thought leadership.